# A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

> **NCT00567710** · PHASE2 · COMPLETED · sponsor: **BioLineRx, Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** BL - 1020
- **DRUG:** BL - 1020
- **DRUG:** Placebo
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00567710
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-07
- **Final completion:** 2009-09
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2010-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00567710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00567710, "A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00567710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*